Active Detachment Involves Inhibition of Cell-Matrix Contacts of Malignant Melanoma Cells by Secretion of Melanoma Inhibitory Activity

Laboratory Investigation

Volumn 83, Issue 11, 2003, Pages 1583-1594

  Bosserhoff, Anja Katrin ^a   Stoll, Raphael ^e   Sleeman, Jonathan P ^c   Bataille, Frauke ^a   Buettner, Reinhard ^b   Holak, Tad A ^d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; ANTIBODY; BETA1 INTEGRIN; CELL PROTEIN; EPITOPE; FIBRONECTIN; MELANOMA INHIBITORY ACTIVITY PROTEIN; PEPTIDE HORMONE; SCLEROPROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CONTACT; CONTROLLED STUDY; DISSOCIATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CROSS REACTIONS; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHA5BETA1; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS;

EID: 0242413754     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000097191.12477.5D     Document Type: Article

References (40)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, and McEwan RN (1987). A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
2. Apfel R, Lottspeich F, Hoppe J, Behl C, Durr G, and Bogdahn U (1992). Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 2:327-336.
3. Bates RC, Lincz LF, and Burns GF (1995). Involvement of integrins in cell survival. Cancer Metastasis Rev 14:191-203.
4. Bergelson JM, Shepley MP, Chan BM, Hemler ME, and Finberg RW (1992). Identification of the integrin VLA-2 as a receptor for echovirus 1 [see comments]. Science 255:1718-1720.
5. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, and Bogdahn U (1994). Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695-5701.
6. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, and Martin R (1989). Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49:5358-5363.
7. Bosserhoff AK, Echtenacher B, Hein R, and Buettner R (2001). Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res 11:417-421.
8. Bosserhoff AK, Hauschild A, Hein R, Schadendorf D, Stockflesh E, Bogenrieder T, Landthaler M, Buettner R, and Stolz W (2000). Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: Results of a German multicenter study. J Invest Dermatol 114:395-396.
9. Bosserhoff AK, Hein R, Bogdahn U, and Buettner R (1996). Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271:490-495.
10. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, and Buettner R (1997). Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153.
11. Bosserhoff AK, Moser M, Hein R, Landthaler M, and Buettner R (1999) In situ expression patterns of melanoma-inhibiting activity (MIA) in malignant melanomas and breast cancers. J Pathol 187:446-454.
12. Boudreau N, Sympson CJ, Werb Z, and Bissell MJ (1995). Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891-893.
13. Burg MA, Grako KA, and Stallcup WB (1998). Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 177:299-312.
14. Clarke AS, Lotz MM, Chao C, and Mercurio AM (1995). Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain. J Biol Chem 270:22673-22676.
15. Dreau D, Bosserhoff AK, White RL, Buettner R, and Holder WD (1999). Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol Res 11:55-61.
16. Esty A (1991). Receptor-specific serum-free cell attachment using a highly stable engineered protein polymer. Am Biotechnol Lab 9:44.
17. Falcioni R, Kennel SJ, Giacomini P, Zupi G, and Sacchi A (1986). Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. Cancer Res 46:5772-5778.
18. Grimm T and Johnson JP (1995). Ectopic expression of carcinoembryonic antigen by a melanoma cell leads to changes in the transcription of two additional cell adhesion molecules. Cancer Res 55:3254-3257.
19. Guba M, Bosserhoff AK, Steinbauer M, Abels C, Anthuber M, Buettner R, and Jauch KW (2000). Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br J Cancer 83:1216-1222.
20. Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL, and Clabby ML (1987). Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem 262:11478-11485.
21. Humphries MJ, Akiyama SK, Komoriya A, Olden K, and Yamada KM (1986). Identification of an alternatively spliced site in human plasma fibronectin that mediates cell type-specific adhesion. J Cell Biol 103:2637-2647.
22. Jacob K, Bosserhoff AK, Wach F, Knuchel R, Klein EC, Hein R, and Buettner R (1995). Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer 60:668-675.
23. Jaenicke R and Rudolph R (1986). Refolding and association of oligomeric proteins. Methods Enzymol 131:218-250.
24. Langholz O, Rockel D, Mauch C, Kozlowska E, Bank I, Krieg T, and Eckes B (1995). Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. J Cell Biol 131:1903-1915.
25. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, and Podhajcer OL (1997). The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108:210-214.
26. Loftus JC, Smith JW, and Ginsberg MH (1994). Integrin-mediated cell adhesion: The extracellular face. J Biol Chem 269:25235-25238.
27. Lougheed JC, Holton JM, Alber T, Bazan JF, and Handel TM (2001). Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc Natl Acad Sci USA 98:5515-5520.
28. Mohri H, Katoh K, Iwamatsu A, and Okubo T (1996). The novel recognition site in the C-terminal heparin-binding domain of fibronectin by integrin alpha 4 beta 1 receptor on HL-60 cells. Exp Cell Res 222:326-332.
29. Mould AP, Komoriya A, Yamada KM, and Humphries MJ (1991). The CS5 peptide is a second site in the IIICS region of fibronectin recognized by the integrin alpha 4 beta 1. Inhibition of alpha 4 beta 1 function by RGD peptide homologues. J Biol Chem 266:3579-3585.
30. Qian F, Vaux DL, and Weissman IL (1994). Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77:335-347.
31. Ruoslahti E (1996). RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697-715.
32. Scott G, Ryan DH, and McCarthy JB (1992). Molecular mechanisms of human melanocyte attachment to fibronectin. J Invest Dermatol 99:787-794.
33. Springer TA (1997). Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci USA 94:65-72.
34. Stoll R, Renner C, Zweckstetter M, Bruggert M, Ambrosius D, Palme S, Engh RA, Golob M, Breibach I, Buettner R, Voelter W, Holak TA, and Bosserhoff AK (2001). The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J 20:340-349.
35. Teixido J, Parker CM, Kassner PD, and Hemler ME (1992). Functional and structural analysis of VLA-4 integrin alpha 4 subunit cleavage. J Biol Chem 267:1786-1791.
36. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, and Glushko V (1986). Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 83:465-469.
37. van Groningen JJ, Bloemers HP, and Swart GW (1995). Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 55:6237-6243.
38. Varner JA, Emerson DA, and Juliano RL (1995). Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Mol Biol Cell 6:725-740.
39. Wach F, Eyrich AM, Wustrow T, Krieg T, and Hein R (1996). Comparison of migration and invasiveness of epithelial tumor and melanoma cells in vitro. J Dermatol Sci 12:118-126.
40. Woods A, McCarthy JB, Furcht LT, and Couchman JR (1993). A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation. Mol Biol Cell 4:605-613.